Pfiz­er said its ex­per­i­men­tal an­ti-PD-1 drug best­ed the cur­rent stan­dard of care in a type of blad­der can­cer where ...

Eli Lilly is expanding its private financing ambitions, partnering with venture capital firm Andreessen Horowitz on a new ...

Moderna CSO, launches Kerna Labs with $6M seed funding to develop AI models for better mRNA drugs, partnering with Julia Peng ...

Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, will step down, the agency confirmed ...

Dyne Therapeutics touted an early-stage study of its RNA treatment for myotonic dystrophy type 1 and has selected the dose it ...

Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors ...

With its new CEO installed this week, City Therapeutics is aiming to capitalize on the momentum in signing a new deal. The ...

Windward Bio, Kardigan, Ouro Medicines & Timberlyne Therapeutics. Three licensed drugs from Chinese firms, while Kardigan has ...

Repare Therapeutics pauses gynecologic cancer drugs lunresertib & camonsertib, shifts focus to early-stage assets RP-1664 & ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...

Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — ...

City Therapeutics broke cover in October with a $135 million Series A and the opportunity for executive chairman John ...